ACE-031 (1mg)

ACE-031 (1mg) – Premium Myostatin Inhibitor Fusion Protein for Muscle Growth Research | Unlock Greater Lean Mass, Strength & Muscle Hypertrophy Potential

Discover the power of advanced muscle regulation with ACE-031 1mg, the high-purity soluble activin receptor type IIB (ActRIIB) fusion protein designed for cutting-edge research into myostatin inhibition, skeletal muscle hypertrophy, and body composition optimization. This innovative research compound acts as a decoy receptor, trapping myostatin and related negative regulators of muscle growth to promote significant increases in lean mass and muscle volume with minimal reliance on traditional training variables. Ideal for laboratories exploring treatments for muscle-wasting conditions, performance models, and metabolic pathways.

Premium Product Overview

ACE-031 (also known as Ramatercept or ActRIIB-IgG1 Fc) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIB linked to the Fc portion of human IgG1. This dimeric structure enables high-affinity binding to myostatin (GDF-8), activins, and other TGF-β superfamily ligands, effectively blocking their inhibitory signaling on muscle growth.

Supplied as a stable lyophilized 1mg vial for easy reconstitution, ACE-031 offers researchers a potent tool with a molecular weight around 58–60 kDa (glycosylated fusion protein) and an extended half-life of approximately 10–15 days. Produced at ≥99% purity (verified by HPLC/LC-MS), this research-grade fusion protein supports precise studies on muscle fiber hypertrophy, lean body mass gains, and related physiological effects.

Key Research Benefits of ACE-031 (Myostatin Inhibitor)

• Enhanced Muscle Growth & Hypertrophy: Inhibits myostatin signaling to increase skeletal muscle mass, fiber cross-sectional area, and overall lean body mass — with studies showing up to 3.3% total lean mass increase and 5.1% thigh muscle volume growth in single-dose models.
• Improved Body Composition: Supports reductions in fat mass alongside muscle gains, while positively influencing bone mineral density and biomarkers of bone formation for comprehensive tissue research.
• Strength & Functional Insights: Promotes greater muscle contractile force and may help model improvements in physical performance, making it valuable for neuromuscular and sarcopenia-related investigations.
• Long-Acting Profile: Extended half-life allows infrequent dosing in research protocols, providing sustained myostatin blockade with potential metabolic and regenerative benefits.

Researchers often describe ACE-031 as a breakthrough “muscle-building trap” for studying hypertrophy without the limitations of conventional anabolic approaches.

Incorporate these naturally for better search engine performance on pages about ACE-031 muscle growth research, myostatin inhibitor peptides, ACE-031 1mg for hypertrophy studies, and premium research peptides for body composition.

Quality Assurance & Usage in Research

Sourced exclusively for laboratory research, ACE-031 1mg reconstitutes smoothly with bacteriostatic water or suitable sterile diluent. Its fusion protein design delivers excellent stability and receptor-trapping efficiency when stored correctly (lyophilized at -20°C, reconstituted solutions refrigerated).

Common Research Protocols (for reference only): Subcutaneous administration in studied models typically ranges from 0.02–3 mg/kg, often as single or infrequent doses (every 2–4 weeks) due to the long half-life. Start with lower concentrations to evaluate response and monitor biomarkers. Always adhere to precise reconstitution, storage, and institutional guidelines for optimal experimental efficacy and safety.

Important Research Considerations

While ACE-031 demonstrates impressive potential for muscle mass and strength increases in controlled research, it is a potent fusion protein intended strictly for laboratory use. Clinical development was discontinued due to safety observations such as epistaxis (nosebleeds), telangiectasias (dilated skin vessels), and other non-muscle-related effects linked to broader ligand binding (including BMP-9/10). Common observations include injection site reactions (erythema) and transient changes in biomarkers. It is not approved by regulatory agencies (FDA, etc.) for human therapeutic, cosmetic, or performance use. Prioritize proper protocols, monitor for vascular or bleeding-related effects, and consult qualified professionals for any application beyond strict lab research.

Elevate your peptide and protein research portfolio with ACE-031 1mg — where targeted myostatin inhibition meets powerful insights into muscle hypertrophy, lean mass gains, and advanced body composition science. Experience the potential of this decoy receptor fusion protein for groundbreaking muscle growth studies.

For research purposes only. Not for human consumption, diagnostic, or therapeutic use. Always comply with local laws and institutional protocols.